Filing Flows › ARS Pharmaceuticals (SPRY) › Guidance & outlook

ARS Pharmaceuticals (SPRY) guidance and outlook

ARS Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 16 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 5, 2026

• Our commercialization strategy for neffy in the United States is focused on achieving market share growth through targeted provider engagement, increasing our share in the existing U.S. epinephrine market of approximately five million prescriptions annually, and laying the groundwork to expand into the broader market over time.
• We believe growth in the existing market can be achieved through account-based sales targeting of high-value prescribers of epinephrine, which account for approximately 44% of the total U.S. market opportunity, as well as the nurses and office staff who often manage the prescription process through fulfillment.
• In addition to our neffy base business, we aim to expand the reach of our intranasal epinephrine technology beyond Type I allergic reactions, including anaphylaxis.
• The interim analysis population was fully enrolled as of May 2026, and we currently expect to report interim Phase 2b data in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program.
• We currently rely on third-party manufacturers and suppliers for neffy and our intranasal epinephrine technology product candidates, and we expect to continue to do so to meet our nonclinical, clinical and commercial activities.
• We expect product revenues to fluctuate in future periods as we continue with the commercial launch of neffy .
• We expect revenues under collaboration agreements to fluctuate in future periods based on our ability to meet various regulatory milestones, and contingent on successfully obtaining regulatory approval for neffy in the licensed regions, commercial milestones, royalties or transfer price earned from our partner’s net sales and the supply of commercial product as set forth in the agreements described earlier.
• In addition, we cannot forecast to what degree our licensing, supply and distribution arrangements would affect our development plans and capital requirements.
• We expect to continue to incur audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, board of director fees, investor relations costs associated with operating as a public company, patent costs and defense, and general and administrative personnel.
• In particular, we expect these resources will allow us to fund commercial manufacturing and sales and marketing activities, general operating activities and working capital requirements, and proof of concept clinical trials of neffy for additional indications.
• We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect.
• Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs through a combination of our existing cash, cash equivalents, short-term investments, equity offerings, debt financings and other capital sources which may include collaborations, strategic alliances, marketing, distribution or licensing arrangements or other arrangements…

ARS Pharmaceuticals' latest quarter

Questions

What does ARS Pharmaceuticals expect?

Our commercialization strategy for neffy in the United States is focused on achieving market share growth through targeted provider engagement, increasing our share in the existing U.S. epinephrine market of approximately five million prescriptions annually, and laying the groundwork to expand into the broader market over time. We believe growth in the existing market can be achieved through account-based sales targeting of high-value prescribers of epinephrine, which account for approximately 44% of the total U.S. market opportunity, as well as the nurses and office staff who often manage the

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.